{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:24:40Z","timestamp":1787667880029,"version":"build-2736575974"},"reference-count":40,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["U24CA231858"],"award-info":[{"award-number":["U24CA231858"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>A pilot clinical trial (NCT03519308) was conducted to evaluate perioperative chemotherapy [nab-paclitaxel, gemcitabine, and cisplatin (NGC)] plus nivolumab, with or without synthetic vitamin D (paricalcitol) in resectable pancreatic ductal adenocarcinoma (PDAC). Preclinical studies were designed with statistical power to match the experimental regimen and compare NGC only with NGC plus synthetic vitamin D [calcipotriol (Cal)] or losartan (Losa; an antihypertensive medication).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Molecular subtyping was applied to enroll patients with epithelial subtype PDAC. Genetically engineered PDAC models (KrasG12D;Trp53R172H;Pdx1-Cre mice, N = 140) were randomized to NGC only and combined therapies. Multiparametric MRI and molecular profiling were integrated to assess treatment-induced effects on stroma, including capillary perfusion and density, matrix collagen content, fibroblast activation protein (FAP) levels and transcriptome changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The clinical trial had limited enrollment (N = 3) but confirmed the safety and feasibility of weekly paricalcitol infusion in combination with multiagent chemotherapy. NGC chemotherapy had a profound impact on stroma, inducing a remarkable reduction in FAP levels accompanied by a significant increase in matrix collagen content; chemotherapy also activated epithelial\u2013mesenchymal transition (EMT) and significantly reduced blood perfusion and capillary density, resulting in features of chemoresistance. Combining NGC with stromal-targeting agents\u2014Cal or Losa\u2014diminished EMT and partially restored perfusion through distinct mechanisms: Cal activates the vitamin D receptor to reprise a quiescent stroma, whereas Losa suppresses TGF\u03b2 to increase lymphocyte infiltration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These findings support further investigations of stromal-directed combination strategies to overcome chemotherapy-induced resistance of PDAC. Dynamic contrast-enhanced MRI may provide a valuable platform to monitor stromal adaptations to therapy in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Results from co-clinical trials integrating MRI and molecular profiling provide a translational rationale for investigating stromal-directed combination strategies in PDAC. These approaches may help preserve chemosensitivity, counteract chemotherapy-induced stromal and vascular remodeling, and overcome adaptive resistance mechanisms that limit durable treatment response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0443","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T17:37:07Z","timestamp":1786383427000},"page":"1983-1992","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0928-1104","authenticated-orcid":false,"given":"Mamta","family":"Gupta","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 1 Department of Radiology, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-5290","authenticated-orcid":false,"given":"Hoon","family":"Choi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 1 Department of Radiology, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-5392","authenticated-orcid":false,"given":"Thomas","family":"Karasic","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 2 Abramson Cancer Center, , Philadelphia, Pennsylvania."},{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 3 Pancreatic Cancer Research Center, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9309-985X","authenticated-orcid":false,"given":"Emma E.","family":"Furth","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 2 Abramson Cancer Center, , Philadelphia, Pennsylvania."},{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 3 Pancreatic Cancer Research Center, , Philadelphia, Pennsylvania."},{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 4 Department of Pathology, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3539-9886","authenticated-orcid":false,"given":"Sydney","family":"Shaffer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 2 Abramson Cancer Center, , Philadelphia, Pennsylvania."},{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 4 Department of Pathology, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3983-0777","authenticated-orcid":false,"given":"Sarah","family":"Englander","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 1 Department of Radiology, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7016-8648","authenticated-orcid":false,"given":"Stephen","family":"Pickup","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 1 Department of Radiology, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4535-2088","authenticated-orcid":false,"given":"Cynthia","family":"Clendenin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 2 Abramson Cancer Center, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2922-4414","authenticated-orcid":false,"given":"Fang","family":"Liu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 5 Center for Clinical Epidemiology and Biostatistics, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6204-1305","authenticated-orcid":false,"given":"Quy","family":"Cao","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 5 Center for Clinical Epidemiology and Biostatistics, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3677-115X","authenticated-orcid":false,"given":"Hee Kwon","family":"Song","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 1 Department of Radiology, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9869-4685","authenticated-orcid":false,"given":"Yong","family":"Fan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 1 Department of Radiology, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5031-5735","authenticated-orcid":false,"given":"Jeffrey","family":"Duda","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 1 Department of Radiology, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2258-0187","authenticated-orcid":false,"given":"James C.","family":"Gee","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 1 Department of Radiology, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1581-0220","authenticated-orcid":false,"given":"Mark","family":"Rosen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 1 Department of Radiology, , Philadelphia, Pennsylvania."},{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 2 Abramson Cancer Center, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-4073","authenticated-orcid":false,"given":"Peter J.","family":"O\u2019Dwyer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 2 Abramson Cancer Center, , Philadelphia, Pennsylvania."},{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 3 Pancreatic Cancer Research Center, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4018-381X","authenticated-orcid":false,"given":"Rong","family":"Zhou","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 1 Department of Radiology, , Philadelphia, Pennsylvania."},{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 2 Abramson Cancer Center, , Philadelphia, Pennsylvania."},{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 3 Pancreatic Cancer Research Center, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"2026082509383775800_bib1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026082509383775800_bib2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.5009\/gnl15465","article-title":"Systemic chemotherapy in advanced pancreatic cancer","volume":"10","author":"Lee","year":"2016","journal-title":"Gut Liver"},{"key":"2026082509383775800_bib3","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.lpm.2019.02.025","article-title":"Chemotherapy for pancreatic cancer","volume":"48","author":"Springfeld","year":"2019","journal-title":"Presse Med"},{"key":"2026082509383775800_bib4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"2026082509383775800_bib5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/SLA.0000000000004155","article-title":"Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus gemcitabine\/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma","volume":"272","author":"Ahmad","year":"2020","journal-title":"Ann Surg"},{"key":"2026082509383775800_bib6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","article-title":"Targeting the tumour stroma to improve cancer therapy","volume":"15","author":"Valkenburg","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2026082509383775800_bib7","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"key":"2026082509383775800_bib8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/00006676-200401000-00006","article-title":"Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins","volume":"28","author":"Miyamoto","year":"2004","journal-title":"Pancreas"},{"key":"2026082509383775800_bib9","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat Genet"},{"key":"2026082509383775800_bib10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"2026082509383775800_bib11","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat Med"},{"key":"2026082509383775800_bib12","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1158\/1078-0432.CCR-16-2411","article-title":"Pancreatic cancer genomes: implications for clinical management and therapeutic development","volume":"23","author":"Dreyer","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026082509383775800_bib13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41575-019-0109-y","article-title":"Molecular subtypes of pancreatic cancer","volume":"16","author":"Collisson","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026082509383775800_bib14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1200\/JCO.2017.74.9564","article-title":"HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel\/gemcitabine versus nab-paclitaxel\/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma","volume":"36","author":"Hingorani","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026082509383775800_bib15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2217\/fon-2017-0338","article-title":"HALO-109-301: a phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer","volume":"14","author":"Doherty","year":"2018","journal-title":"Future Oncol"},{"key":"2026082509383775800_bib16","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"key":"2026082509383775800_bib17","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1200\/JCO.2015.62.8719","article-title":"Randomized phase Ib\/II study of gemcitabine plus placebo or vismodegib, a Hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer","volume":"33","author":"Catenacci","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026082509383775800_bib18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cell.2014.08.007","article-title":"Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy","volume":"159","author":"Sherman","year":"2014","journal-title":"Cell"},{"key":"2026082509383775800_bib19","doi-asserted-by":"publisher","first-page":"26835","DOI":"10.1073\/pnas.1914915116","article-title":"Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma","volume":"116","author":"Porter","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026082509383775800_bib20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","article-title":"Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice","volume":"7","author":"Hingorani","year":"2005","journal-title":"Cancer Cell"},{"key":"2026082509383775800_bib21","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41598-023-27787-x","article-title":"Assessment of diffusion-weighted MRI in predicting response to neoadjuvant chemotherapy in breast cancer patients","volume":"13","author":"Hottat","year":"2023","journal-title":"Sci Rep"},{"key":"2026082509383775800_bib22","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1158\/1078-0432.CCR-18-2276","article-title":"Dynamic contrast-enhanced MRI detects responses to stroma-directed therapy in mouse models of pancreatic ductal adenocarcinoma","volume":"25","author":"Cao","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026082509383775800_bib23","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.3390\/cancers14164017","article-title":"DWI metrics differentiating benign intraductal papillary mucinous neoplasms from invasive pancreatic cancer: a study in GEM models","volume":"14","author":"Romanello Joaquim","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026082509383775800_bib24","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1158\/1078-0432.CCR-24-4049","article-title":"Multimetric MRI captures early response and acquired resistance of pancreatic cancer to KRAS inhibitor therapy","volume":"31","author":"Gupta","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026082509383775800_bib25","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/mrm.24127","article-title":"Magnetization transfer MRI in pancreatic cancer xenograft models","volume":"68","author":"Li","year":"2012","journal-title":"Magn Reson Med"},{"key":"2026082509383775800_bib26","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.3390\/tomography8050178","article-title":"Dynamic contrast-enhanced MRI in the abdomen of mice with high temporal and spatial resolution using stack-of-stars sampling and KWIC reconstruction","volume":"8","author":"Pickup","year":"2022","journal-title":"Tomography"},{"key":"2026082509383775800_bib27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/mrm.20143","article-title":"Simultaneous measurement of arterial input function and tumor pharmacokinetics in mice by dynamic contrast enhanced imaging: effects of transcytolemmal water exchange","volume":"52","author":"Zhou","year":"2004","journal-title":"Magn Reson Med"},{"key":"2026082509383775800_bib28","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1158\/1078-0432.CCR-23-1405","article-title":"A pilot study of paricalcitol plus nanoliposomal irinotecan and 5-FU\/LV in advanced pancreatic cancer patients after progression on gemcitabine-based therapy","volume":"29","author":"Grierson","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026082509383775800_bib29","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026082509383775800_bib30","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/jco.2023.41.4_suppl.719","article-title":"A multicenter, randomized phase II study of total neoadjuvant therapy (TNT) with FOLFIRINOX (FFX) and SBRT, with or without losartan (L) and nivolumab (N) in borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC)","volume":"41","author":"Hong","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026082509383775800_bib31","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.gendis.2022.10.019","article-title":"The role of TGF-\u03b2 in the tumor microenvironment of pancreatic cancer","volume":"10","author":"Luo","year":"2023","journal-title":"Genes Dis"},{"key":"2026082509383775800_bib32","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1158\/1078-0432.CCR-22-1630","article-title":"Addition of losartan to FOLFIRINOX and chemoradiation reduces immunosuppression-associated genes, Tregs, and FOXP3+ cancer cells in locally advanced pancreatic cancer","volume":"29","author":"Boucher","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026082509383775800_bib33","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3748\/wjg.v18.i8.840","article-title":"Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance","volume":"18","author":"Shi","year":"2012","journal-title":"World J Gastroenterol"},{"key":"2026082509383775800_bib34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12876-015-0340-0","article-title":"Fibroblast activation protein-\u03b1-expressing fibroblasts promote the progression of pancreatic ductal adenocarcinoma","volume":"15","author":"Kawase","year":"2015","journal-title":"BMC Gastroenterol"},{"issue":"7_Supplement","key":"2026082509383775800_bib35","doi-asserted-by":"publisher","first-page":"CT214","DOI":"10.1158\/1538-7445.am2024-ct214","article-title":"Abstract CT214: paricalcitol addition to chemotherapy in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PINBALL)","volume":"84","author":"Propper","year":"2024","journal-title":"Cancer Res"},{"key":"2026082509383775800_bib36","doi-asserted-by":"publisher","first-page":"oyae323","DOI":"10.1093\/oncolo\/oyae323","article-title":"Pembrolizumab \u00b1 paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction","volume":"30","author":"Chung","year":"2025","journal-title":"Oncologist"},{"key":"2026082509383775800_bib37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12885-025-14512-2","article-title":"Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemcitabine and NAB-paclitaxel therapy in advanced pancreatic cancer","volume":"26","author":"Easty","year":"2026","journal-title":"BMC Cancer"},{"key":"2026082509383775800_bib38","doi-asserted-by":"publisher","first-page":"oyag232","DOI":"10.1093\/oncolo\/oyag232","article-title":"A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer","volume":"31","author":"Viniotis","year":"2026","journal-title":"Oncologist"},{"issue":"22_Supplement","key":"2026082509383775800_bib39","doi-asserted-by":"publisher","first-page":"PR-002","DOI":"10.1158\/1538-7445.panca21-pr-002","article-title":"Abstract PR-002: a phase II pilot trial of nivolumab (N) + albumin bound paclitaxel (AP) + paricalcitol (P) + cisplatin (C) + gemcitabine (G) (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC)","volume":"81","author":"Borazanci","year":"2021","journal-title":"Cancer Res"},{"key":"2026082509383775800_bib40","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s43018-026-01165-8","article-title":"Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial","volume":"7","author":"Perez","year":"2026","journal-title":"Nat Cancer"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0443\/3820532\/crc-26-0443.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/8\/1983\/3824388\/crc-26-0443.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/8\/1983\/3824388\/crc-26-0443.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:38:47Z","timestamp":1787665127000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/8\/1983\/787653\/Co-Clinical-Evaluation-of-Synthetic-Vitamin-D-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0443","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.33329350","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33329333","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33329321","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33329342","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33329353","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33329330","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33329309","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33329315","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33329348","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33329336","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33329324","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33329356","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33329312","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33329345","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33329318","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33329306","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33329339","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33329327","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8672840","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}